Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | NOTCH1 wild-type RB1 wild-type |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
NOTCH1 wild-type RB1 wild-type | T-cell adult acute lymphocytic leukemia | sensitive | Prednisolone + Ribociclib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Kisqali (ribociclib) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). | 28151717 | |
NOTCH1 wild-type RB1 wild-type | T-cell adult acute lymphocytic leukemia | decreased response | Asparaginase + Ribociclib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Kisqali (ribociclib) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). | 28151717 | |
NOTCH1 wild-type RB1 wild-type | T-cell adult acute lymphocytic leukemia | sensitive | Bortezomib + Ribociclib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Kisqali (ribociclib) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). | 28151717 | |
NOTCH1 wild-type RB1 wild-type | T-cell adult acute lymphocytic leukemia | decreased response | Mercaptopurine + Ribociclib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Kisqali (ribociclib) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). | 28151717 | |
NOTCH1 wild-type RB1 wild-type | T-cell adult acute lymphocytic leukemia | sensitive | JQ1 + Ribociclib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Kisqali (ribociclib) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). | 28151717 | |
NOTCH1 wild-type RB1 wild-type | T-cell adult acute lymphocytic leukemia | sensitive | Everolimus + Ribociclib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of Kisqali (ribociclib) and Afinitor (everolimus) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 resulted in decreased Rb1 phosphorylation and a greater inhibition of cell growth compared to either agent alone in culture, and prolonged survival in cell-line xenograft models (PMID: 28151717). | 28151717 | |
NOTCH1 wild-type RB1 wild-type | T-cell adult acute lymphocytic leukemia | sensitive | Ribociclib | Preclinical - Cell culture | Actionable | In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 demonstrated sensitivity to treatment with Kisqali (ribociclib) in culture, resulting in inhibition of cell growth (PMID: 28151717). | 28151717 | |
NOTCH1 wild-type RB1 wild-type | T-cell adult acute lymphocytic leukemia | conflicting | Dexamethasone + Ribociclib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and NOTCH1 resulted in decreased cell viability and reduced phosphorylation of Rb1 in culture, however, survival did not differ between xenograft models treated with the combination or Kisqali (ribociclib) alone (PMID: 28151717). | 28151717 | |
NOTCH1 wild-type RB1 wild-type | T-cell adult acute lymphocytic leukemia | decreased response | Methotrexate + Ribociclib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Kisqali (ribociclib) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). | 28151717 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|